---
type: "NewsArticle"
title: "US agencies open process to schedule concentrated 7-OH products"
description: "FDA’s July 13 update described a temporary-scheduling proposal for concentrated 7-OH and synthetic derivatives, distinguishing the process from a final order."
resource: "https://nootropikler.com/news/dea-begins-7-oh-scheduling-process"
tags: ["brain-health", "evidence-limits", "safety"]
timestamp: 2026-10-04T23:57:49Z
language: "en"
---

# US agencies open process to schedule concentrated 7-OH products

FDA’s July 13 update described a temporary-scheduling proposal for concentrated 7-OH and synthetic derivatives, distinguishing the process from a final order.

Author: Nootropik News Editorial Team
Published: 2026-10-04T23:57:49Z
Update: 2026-10-04T23:57:49Z
News/source date: 2026-07-13
Production: AI-assisted sourced summary and translation; no independent medical expert review is claimed.

## What happened

FDA’s July 13, 2026 update described DEA’s July 1 notice of intent to start temporary scheduling of 7-hydroxymitragynine above a proposed threshold and three synthetic derivatives: mitragynine pseudoindoxyl, MGM-15 and MGM-16. HHS opened a separate public-comment process about the threshold. The source records the agencies’ actions at that point in July; it does not announce that the notice itself had already become a final scheduling order.

## Why it matters

The agencies said the proposed action targeted concentrated and synthetic 7-OH products, rather than natural kratom leaf containing only naturally occurring trace amounts. HHS asked for evidence about the amount or concentration representing an imminent public-safety hazard and possible alternative ways to express that threshold. This distinction matters because leaf material, concentrated extracts and synthetic compounds are not interchangeable exposure categories merely because their marketing uses the same botanical name.

## Scope and limitations

FDA explained that a temporary order could be issued no sooner than 30 days after the notice, subject to the statutory conditions. A comment period, a proposal and a final order are different steps; the July update should not be used as a complete account of the law at a later date. This is U.S. regulatory news about opioid-related substances, not evidence of cognitive benefit or a legal determination for Turkey. The original agency page is the reference for the historical update.

## Sources

- [Hiding in Plain Sight: 7-OH Products — July 13, 2026 update](https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products) — 2026-07-13
